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INTRODUCTION 
The anthracycline antibiotics daunomycin and 14-hydroxydaunomycin 
(adriamycin, ADR) have been shown to be very effective in the 
treatment of a number of malignancies (1,2). Besides the non- 
-specific side effects of cytostatic agents, adriamycin exerts a 
specific toxic activity on the heart which may eventually lead to 
a life-threatening congestive heart failure when a cumulative dose 
of 550 mg/m2 has been exceeded (1,2). To effect a decrease in 
cardiotoxicity we are developing adriamycin-polymer conjugates which 
are not taken up by heart muscle cells but are readily incorporated 
in tumor cells. After internalization of a macromolecular substance 
by endocytosis a phagosome is formed which is then fused with a 
lysozome (Fig. 1). The substance is then exposed to many digestive 
enzymes at an acidic pH (4-5) ( 3 ) .  We have concentrated on the use 
of poly(a-L-glutamic acid)(PGA) as a carrier, because this polymer 
can readily be degraded by lysozomal enzymes and is rather plasma- 
-stable. After partial derivatization the conjugate will be water- 
-soluble owing to residual carboxylic acid groups. 
RESULTS AND DISCUSSION 
The adriamycin moiety was covalently bound to PGA with various 
labile linkages including acylhydrazone (Fig. 2) and amide either 
without or with various peptide spacers (Fig. 3 ) .  Details about 
the syntheses of these conjugates will be described elsewhere ( 4 , 5 ) .  
The cytotoxic activity of polymeric conjugates with either complex- 
-bound or covalently-bound adriamycin was evaluated using in vitro 
Ll2lO clonogenic and B16 melanoma liquid assays (Table 1). These 
data indicate that adriamycin when complexed or linked to the 
carrier with an acylhydrazone bond at C-13 retains a significant 
cytotoxicity. The latter type of covalent bond appears promising 
for adriamycin prodrugs, although the polymeric conjugate as well 
as the acylhydrazide tend to become insoluble on standing for 
reasons still under study. Amide-bound prodrugs of adriamycin are 
found to be stable in plasma for at least 4 8  hours in accordance 
with their possible applicability as an endocellular release system. 
The cytotoxicity of these conjugates can be improved by the use of 
peptide spacers but remains relatively low. The data suggest that 
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Table 1. Cytotoxic activities, expressed as dose w i t h  50 % inhibition 
of cell growth (IDso) of adriamycin prodrugs 
IDSO ID50 
TYPE CODE- LOAD Ll2lO assay B16 assay 
(mole-%) (ng ADR/ml) (ng ADR/ml) 
Free drug A 
Acylhydrazone P -H-A 3 
Con jugate P2-A 
Complex P-A/A 
P3-GGL-A/A 
P -GGL-A 
P G-GGL-A 
P -GT-GGL-A 
P -GGL-A 
P7-GGGL-A 
P8-CGGL-A] 
P8-[GGGL-Al 
3 Spacer 
2- 
7 
13/0.4 
5 
6/3.3 
76/4/3 
96/4.3 
95; 61/10 
100;53/9 
89/8 
84/8 
4.4/4.4 
4.5/4.5 
21/24 
53-71 
1100-4100 
24-39 
- 
200 
1100/3300 
>2200 
3000 
560 
>65000 
>65000 
- 
4-5 
17 
- 
2-4 
70 
210 
180 
220 
200 
>>650 
>>650 
* indices indicate batch number; A = adriamycine; H = acylhydrazone; 
P = poly(a-L-glutamic aci& G = Gly; L = Leu; T = Tyr 
in the conjugates prepared thus far and having peptide spacers with 
up to 5 amino acid residues,the velocity of the enzymatic release 
of adriamycin by lysozomal enzymes inside tumor cells is still too 
low for efficient drug action. Using the same batch of PGA, the 
increase in spacer length from three to four amino acid residues 
improves the cytotoxicity fivefold (P -GGL-A and P -GGGL-A), 
consistent with an increased accessibility of the leucyl-adriamycin 
bond to enzymes. On the other hand, on decreasing the load of 
peptide spacer from 84-89 mole-% to 4.5 mole-% the cytotoxic 
activity decreases to very low values (P -[GGL-AI and P8-CGGG1-Al) 
which contradicts the expected decrease in steric hindrance to 
enzymatic hydrolysis. On the basis of these results a m r e  detailed 
study on the enzymatic degradation of macromolecular prodrugs using 
PGA and derivatives as the carrier including the effects of pH (6) 
seems warranted. Such studies,including the use of p-nitroaniline 
as a model drug (3),are currently in progress. 
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